Approved SMA drug connects gene ends like a loop, boosting its activity

Scientists say these findings expand therapeutic potential of Spinraza

Written by Steve Bryson, PhD |

A close-up look at a 3D image of a DNA strand highlights its twisted-ladder-like structure.

(Image from iStock)

  • The SMA drug Spinraza corrects splicing defects in a key gene and creates a loop that further boosts its activity, a new study found.
  • The scientists says these findings present new therapeutic avenues that could help optimize treatments for the rare disease.
  • Spinraza, approved a decade ago, was the first treatment to address the underlying causes of SMA.

Spinraza (nusinersen), an approved therapy for people with spinal muscular atrophy (SMA), corrected the splicing defects of the SMN2 gene as designed, but it also brought the two ends of the SMN2 gene into closer physical contact, like a loop, further boosting the gene’s activity.

The looping effect revealed in the study was independent of Spinraza’s intended mechanism of action, the researchers noted — a result that they say expands the therapeutic potential of such splicing-correcting treatments.

Given by injection into the spinal canal, Spinraza was the first disease-modifying therapy to be approved for SMA, winning regulatory clearance a decade ago.

The study detailing these new findings, titled “An SMN2 splicing-correcting antisense oligonucleotide promotes gene looping and transcription activation,” was published in the journal Molecular Cell.

Recommended Reading
A circular seal with

FDA approves high-dose Spinraza regimen for new, existing SMA patients

In most cases of SMA, SMN1 gene mutations disrupt the production of SMN, a protein that’s essential for the health of nerve cells that control muscle function. Without functional SMN, these nerve cells, called motor neurons, die off, leading to symptoms of muscle wasting and weakness.

Humans also have a second gene, called SMN2, that produces SMN. However, due to a natural process called alternative splicing, less functional SMN protein is made. As a result, SMN2 cannot fully compensate for the loss of SMN1.

Spinraza, approved for adults and children with SMA, contains an antisense oligonucleotide (ASO), a short strand of genetic material that’s designed to correct SMN2 splicing. In this way, more functional SMN is produced and the underlying cause of the disease is targeted.

Scientists still making discoveries about SMA drug Spinraza

A team led by scientists in Argentina recently discovered that Spinraza also promotes the addition of a silencing chemical tag, called H3K9me2, to the histone proteins that package DNA. This modification tightens interactions between histones and DNA, inadvertently reducing SMN2 gene activity and SMN protein production.

To address this problem, the researchers added histone deacetylase (HDAC) inhibitors, such as valproic acid — an anti-seizure medication that has been studied as an experimental treatment for SMA. HDAC inhibitors block the activity of enzymes called histone deacetylases, which remove acetyl groups from histones, thereby boosting gene activity.

Despite its ability to increase SMN2 activity, in clinical trials, valproic acid failed to improve motor function in people with SMA. Moreover, HDAC inhibitors can have widespread effects on many other genes and proteins, which can lead to unwanted side effects.

Now, the research team sought to determine whether they could increase SMN2 activity specifically using targeted histone acetylation, a molecular activation tag that acts like an on-off switch moving to the on position.

In cells, the researchers confirmed that Spinraza increased the H3K9me2 silencing mark near the end of the SMN2 gene. The team also discovered that the therapy added the silencing mark at the promoter, the gene’s starting region far upstream. Consistently, depleting the enzymes that add the H3K9me2 silencing mark, or the protein that reads the mark, boosted Spinraza-enhanced SMN2 activity.

Recommended Reading
A close-up view of a strand of DNA highlights its double-helix structure.

Scientists discover key mechanism for altered SMN2 gene processing

New research shows drug increasing ‘looping’ in gene

To test the impact of targeted histone acetylation, the team used an RNA probe that bound selectively to the end of the SMN2 gene. The probe was fused to p300, an enzyme that adds acetyl groups to adjacent histones to increase gene activity. Experiments showed this boosted the Spinraza-enhanced activity of SMN2, similar to that of HDAC inhibitors. In contrast, blocking p300’s action abolished this enhancement.

As expected, the team confirmed that targeting the end of the SMN2 gene leads to localized histone acetylation with and without Spinraza. Because Spinraza also added the H3K9me2 silencing mark at the promoter, the researchers then sought to test whether targeted histone acetylation had the same effect.

Targeting the end of the SMN2 gene did indeed cause histone acetylation at the promoter region, but only in the absence of Spinraza, the researchers noted. Importantly, the team found that when the RNA probe was directed to the gene’s promoter, it not only corrected SMN2 alternative splicing but also enhanced SMN2 levels elicited by Spinraza.

The researchers noted that localized histone acetylation, either at the promoter or at the end region, plays distinct roles in controlling gene activity and alternative splicing.

Because SMN2‘s promoter is far from the end of the gene, the results so far suggest that the two ends of the gene may interact directly, forming a loop. To test this, the team used a method that measures how often distant DNA regions contact each other.

When cells were treated with Spinraza, the contact frequency between the SMN2 promoter and its end region increased significantly. Targeting the RNA probe for histone acetylation near the end region of SMN2 also increased promoter contacts, as did targeting it to the promoter. In addition, Spinraza increased promoter activity and, thus, SMN2 activity, independent of its intended splicing correlations.

The “finding that looping was increased by [Spinraza] revealed an unexpected property of ASOs,” the team wrote. “We foresee that the results in this report will open relevant avenues for the world of ASO therapies.”

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.